Rosiptor manufacturers
- Rosiptor
-
- $10.00
-
2026-09-16
- CAS:782487-28-9
- Min. Order: 1ASSAYS
- Purity: 99%
- Supply Ability: 1 ton
- Semaglutide
-
-
2026-09-16
- CAS:782487-28-9
- Min. Order: 1g
- Purity: More Than 99%
- Supply Ability: 100kg/Month
- Semaglutide
-
-
2026-09-16
- CAS:782487-28-9
- Min. Order: 1g
- Purity: 98%min
- Supply Ability: 1000g
|
| | Rosiptor Basic information |
| Product Name: | Rosiptor | | Synonyms: | AQX10;Rosiptor;AQX-1125;AQX1125;ROSIPTOR;Rosiptor(AQX-1125);AQX 1125
(AQX-1125;semaglutide API;Cyclohexanemethanol, 2-[(3aS,4R,5S,7aS)-4-(aminomethyl)octahydro-7a-methyl-1-methylene-1H-inden-5-yl]-5-hydroxy-2-methyl-, (1S,2R,5S)-;Semaglutide-fermented | | CAS: | 782487-28-9 | | MF: | C20H35NO2 | | MW: | 321.5 | | EINECS: | 200-001-8 | | Product Categories: | APIs;782487-28-9 | | Mol File: | 782487-28-9.mol |  |
| | Rosiptor Chemical Properties |
| Boiling point | 451.6±45.0 °C(Predicted) | | density | 1.07±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 150 mg/mL (466.56 mM) | | pka | 15.05±0.10(Predicted) | | form | Solid | | color | White to off-white | | InChI | InChI=1S/C20H35NO2/c1-13-4-5-17-16(11-21)18(7-9-19(13,17)2)20(3)8-6-15(23)10-14(20)12-22/h14-18,22-23H,1,4-12,21H2,2-3H3/t14-,15+,16+,17+,18+,19-,20+/m1/s1 | | InChIKey | MDEJTPWQNNMAQF-BVMLLJBZSA-N | | SMILES | [C@H]1(CO)C[C@@H](O)CC[C@@]1([C@H]1CC[C@@]2(C)[C@]([H])([C@@H]1CN)CCC2=C)C |
| | Rosiptor Usage And Synthesis |
| Description | Rosiptor (AQX-1125) is a selective and orally active phosphatase SHIP1 activator with anti-inflammatory effects. It inhibits Akt phosphorylation, inflammatory mediator production and leukocyte chemotaxis in vitro. | | Uses | Rosiptor has been used in trials studying the treatment of COPD, Atopic Dermatitis, Interstitial Cystitis, and Bladder Pain Syndrome. | | Biological Activity | Rosiptor is a small-molecule SHIP1 activator.The activating effect of Rosiptor on SHIP1 is 28% at 100 μM in the native enzyme but no effect of Rosiptor is observed when the SHIP1δC2 enzyme is used. Rosiptor induces a concentration-dependent decrease in Akt phosphorylation in MOLT-4 cells, while it fails to affect Akt phosphorylation in Jurkat cells. At 0.1 μM Rosiptor the inhibition amounts to an average of 34%, while at 10 μM the inhibition amounts to an average of 82% in two independent experiments. Rosiptor also induces a concentration-dependent decrease in the production of multiple pro-inflammatory mediators in this system, without affecting cell viability. Rosiptor dose dependently inhibits chemotaxis of most cell types at low micromolar concentrations independent of the chemotactic stimulus. | | in vivo | Rosiptor (3-30 mg/kg; p.o.; daily for 3 days) significantly reduces the total number of BAL leukocytes in NSC-125066-challenged mice and reduces MPO activity[2].
Rosiptor (10 mg/kg; p.o.) has the Cmax value of 0.830 μM and the t1/2 value of 5.2 hours. AQX-1125 also exhibits >80% oral bioavailability[1]. | Animal Model: | 6-8 weeks old male CD-1 mice[1] | | Dosage: | 3, 10, 30 mg/kg | | Administration: | p.o.; daily for 3 days | | Result: | Significantly reduced the total number of BAL leukocytes in NSC-125066-challenged mice, up to a maximum of 60% at 7 days and 63% at 21 days at 30 mg/kg; Reduced MPO activity by 54% at Day 7 and by 74% at Day 21 at 30 mg/kg. |
| Animal Model: | Male Sprague-Dawley rats[1] | | Dosage: | 10 mg/kg (Pharmacokinetic Study) | | Administration: | Oral administration | | Result: | The Cmax value is 0.830 μM and the t1/2 value is 5.2 hours. |
|
| | Rosiptor Preparation Products And Raw materials |
|